Merck
CN
所有图片(1)

文件

C1231

SAFC

胆固醇、植物的

SyntheChol®

登录查看公司和协议定价
所有图片(1)
别名:
胆固醇, 合成胆固醇, 3β-羟基-5-胆甾烯, 5-胆甾烯-3β-醇
经验公式（希尔记法）:
C27H46O
CAS号:
57-88-5
分子量:
386.65
Beilstein:
1915888
EC 号:
200-353-2
MDL编号:
MFCD00003646

生物来源

synthetic

质量水平

500

Agency

JP
NF
Ph. Eur.

检测方案

≥98%

形式

crystals

bp

360 °C (lit.)

mp

147-149 °C (lit.)

密度

1.067 g/mL at 25 °C (lit.)

适用性

suitable for manufacturing use

运输

dry ice

储存温度

−20°C (−15°C to −25°C)

SMILES string

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

InChI

1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25,28H,6-8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1

InChI key

HVYWMOMLDIMFJA-DPAQBDIFSA-N

Gene Information

human ... POLA1(5422) , TOP2A(7153)
rat ... Ar(24208) , Polb(29240)

正在寻找类似产品? Visit 产品对比指南

相关类别

生化/生理作用

所有生物膜的主要成分；总脑脂质中约25%为胆固醇。

制备说明

由非动物源物质合成

法律信息

SyntheChol is a registered trademark of Merck KGaA, Darmstadt, Germany

储存分类代码

11 - Combustible Solids

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

为方便起见，与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码？

在网站页面上，产品编号会附带包装尺寸/数量一起显示（例如：T1503-25G）。请确保 在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503
货号
-
25G
包装规格/数量

其它示例：

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题？欢迎随时联系我们技术服务 寻求帮助

批号可以在产品标签上"批“ （Lot或Batch）字后面找到。

Aldrich 产品

  • 如果您查询到的批号为 TO09019TO 等，请输入去除前两位字母的批号：09019TO。

  • 如果您查询到的批号含有填充代码（例如05427ES-021），请输入去除填充代码-021的批号：05427ES。

  • 如果您查询到的批号含有填充代码（例如 STBB0728K9），请输入去除填充代码K9的批号：STBB0728。

未找到您寻找的产品？

部分情况下，可能未在线提供COA。如果搜索不到COA，可在线索取。

索取COA

James I Dower et al.
The American journal of clinical nutrition, 101(5), 914-921 (2015-05-03)
Prospective cohort studies showed inverse associations between the intake of flavonoid-rich foods (cocoa and tea) and cardiovascular disease (CVD). Intervention studies showed protective effects on intermediate markers of CVD. This may be due to the protective effects of the flavonoids
Steven A Grover et al.
The lancet. Diabetes & endocrinology, 3(2), 114-122 (2014-12-09)
Despite the increased risk of cardiovascular disease and type 2 diabetes associated with excess bodyweight, development of a clinically meaningful metric for health professionals remains a challenge. We estimated the years of life lost and the life-years lost from diabetes
Bo Angelin et al.
Journal of internal medicine, 277(3), 331-342 (2014-04-24)
Liver-selective thyromimetic agents could provide a new approach for treating dyslipidaemia. We performed a multicentre, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of eprotirome, a liver-selective thyroid hormone receptor agonist, in 98 patients with primary hypercholesterolaemia. After
Michael J Pencina et al.
The New England journal of medicine, 370(15), 1422-1431 (2014-03-22)
The 2013 guidelines of the American College of Cardiology and the American Heart Association (ACC-AHA) for the treatment of cholesterol expand the indications for statin therapy for the prevention of cardiovascular disease. Using data from the National Health and Nutrition
Peter Libby et al.
Immunity, 38(6), 1092-1104 (2013-07-03)
According to the traditional view, atherosclerosis results from a passive buildup of cholesterol in the artery wall. Yet, burgeoning evidence implicates inflammation and immune effector mechanisms in the pathogenesis of this disease. Both innate and adaptive immunity operate during atherogenesis
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门